Enfortumab vedotin
- Generic Name
- Enfortumab vedotin
- Brand Names
- 备思复
Drug Screening Using IMD in Bladder Cancer
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma
- Interventions
- Device: Implantable Micro-DeviceDrug: Gemcitabine/Cisplatin IDrug: Methotrexate/Vinblastine/Doxorubicin/Cisplatin/AvelumabDrug: Gemcitabine/Cisplatin IIDrug: Gemcitabine/CarboplatinDrug: Methotrexate/Vinblastine/Doxorubicin/CisplatinDrug: Gemcitabine/Cisplatin/NivolumabDrug: Paclitaxel/Docetaxel/IfosfamideDrug: Gemcitabine/Carboplatin/Nivolumab
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06204614
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Sacituzumab Govitecan Plus EV in Metastatic UC
- Conditions
- Bladder CancerUrothelial CancerMetastatic Urothelial CarcinomaMetastatic Urothelial Carcinoma of the Renal Pelvis and Ureter
- Interventions
- Drug: Sacituzumab Govitecan (SG)
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT04724018
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 808
- Registration Number
- NCT04700124
- Locations
- 🇯🇵
Gifu University Hospital ( Site 1513), Gifu, Japan
🇷🇺Volgograd Regional Uronephrological Center ( Site 0870), Volzhsky, Volgogradskaya Oblast, Russian Federation
🇺🇦Municipal Non-profit Enterprise of Kharkiv Regional Council RCSDRPP ( Site 0965), Kharkiv, Kharkivska Oblast, Ukraine
An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
- Conditions
- Locally Advanced or Metastatic Urothelial Carcinoma (UC)
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT04136808
- Locations
- 🇺🇸
UCLA Hematology Oncology, Los Angeles, California, United States
🇺🇸John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸Northwestern University Medical Center, Chicago, Illinois, United States
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
- Conditions
- Renal Pelvis NeoplasmsCarcinoma, Transitional CellUrinary Bladder NeoplasmsUrologic NeoplasmsUrothelial CancerUreteral NeoplasmsUrethral Neoplasms
- Interventions
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 348
- Registration Number
- NCT03288545
- Locations
- 🇺🇸
Piedmont Cancer Institute, Atlanta, Georgia, United States
🇺🇸Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.